Nick Leschly Biography and Net Worth

CEO of bluebird bio

Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.

What is Nick Leschly's net worth?: The estimated net worth of Nick Leschly is at least $4.36 million as of January 5th, 2024. Mr. Leschly owns 1,085,476 shares of bluebird bio stock worth more than $4,358,186 as of March 6th. This net worth approximation does not reflect any other assets that Mr. Leschly may own. Learn More about Nick Leschly's net worth.
How do I contact Nick Leschly?: The corporate mailing address for Mr. Leschly and other bluebird bio executives is 60 BINNEY STREET, CAMBRIDGE MA, 02142. bluebird bio can also be reached via phone at (339) 499-9300 and via email at investor@bluebirdbio.com. Learn More on Nick Leschly's contact information.
Has Nick Leschly been buying or selling shares of bluebird bio?: Nick Leschly has not been actively trading shares of bluebird bio during the past quarter. Most recently, Nick Leschly sold 214 shares of the business's stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $156.00, for a transaction totalling $33,384.00. Following the completion of the sale, the director now directly owns 14,007 shares of the company's stock, valued at $2,185,092. Learn More on Nick Leschly's trading history.
Who are bluebird bio's active insiders?: bluebird bio's insider roster includes Jason Cole (Insider), David Davidson (Insider), Nick Leschly (CEO), Andrew Obenshain (Insider), and Jessica Whitten (CAO). Learn More on bluebird bio's active insiders.
Are insiders buying or selling shares of bluebird bio?: During the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 396 shares worth more than $3,233.92. The most recent insider tranaction occured on February, 3rd when insider Thomas J Klima sold 122 shares worth more than $901.58. Insiders at bluebird bio own 1.4% of the company. Learn More about insider trades at bluebird bio.
Information on this page was last updated on 2/3/2025.

Nick Leschly Insider Trading History at bluebird bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/11/2023	Sell	214	$156.00	$33,384.00	14,007
1/10/2022	Sell	118	$188.00	$22,184.00
5/3/2021	Sell	22	$603.00	$13,266.00	15,334
1/5/2021	Sell	16	$899.00	$14,384.00	4,867
12/2/2020	Sell	22	$924.00	$20,328.00	4,885
10/2/2020	Sell	22	$1,055.40	$23,218.80	4,928
9/3/2020	Sell	21	$1,172.00	$24,612.00	4,951
7/2/2020	Sell	22	$1,231.40	$27,090.80	4,995
6/2/2020	Sell	22	$1,280.80	$28,177.60	5,034
1/7/2020	Sell	508	$1,799.40	$914,095.20	2,835
1/7/2019	Sell	368	$2,272.80	$836,390.40	1,034
1/5/2018	Sell	271	$3,467.60	$939,719.60	8,550
12/13/2017	Sell	5,874	$3,681.60	$21,625,718.40	14,661
11/1/2017	Sell	106	$2,903.40	$307,760.40	12,874
10/23/2017	Sell	352	$2,902.80	$1,021,785.60	12,952
10/20/2017	Sell	167	$2,900.40	$484,366.80	12,952
10/17/2017	Sell	541	$2,901.00	$1,569,441.00	13,120
9/1/2017	Sell	2,341	$2,445.40	$5,724,681.40	14,468
8/30/2017	Sell	1,283	$2,303.60	$2,955,518.80	16,968
6/27/2017	Sell	1,249	$2,161.00	$2,699,089.00	18,032
12/8/2015	Buy	484	$1,035.00	$500,940.00	15,662
9/8/2015	Sell	6,249	$2,704.80	$16,902,295.20	12,325
12/1/2014	Sell	120	$794.00	$95,280.00
11/3/2014	Sell	1,249	$833.60	$1,041,166.40
10/24/2014	Sell	1,694	$804.40	$1,362,653.60
10/1/2014	Sell	399	$691.00	$275,709.00
9/2/2014	Sell	514	$769.00	$395,266.00
8/1/2014	Sell	399	$672.40	$268,287.60
7/3/2014	Sell	1,114	$797.20	$888,080.80
6/20/2014	Sell	853	$801.20	$683,423.60
6/16/2014	Sell	2,146	$800.40	$1,717,658.40
6/2/2014	Sell	249	$444.20	$110,605.80
5/1/2014	Sell	249	$401.40	$99,948.60	15,215

See Full Table

Nick Leschly Buying and Selling Activity at bluebird bio

bluebird bio Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Today's Range

Now: $4.11

$3.86

$4.13

50 Day Range

MA: $7.11

$3.80

$9.92

2 Week Range

Now: $4.11

$3.56

$33.20

Volume

213,848 shs

Average Volume

368,324 shs

Market Capitalization

$39.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76